angn - ANGN STOCK NEWS

Angion Biomedica Corp. (NASDAQ:ANGN) announced its participation in two upcoming investment conferences in March 2022, focusing on fibrotic diseases. Dr. Jay Venkatesan, the company's President and CEO, will join a kidney disease/fibrosis panel at the Cowen 42nd Annual Healthcare Conference on March 9 and a Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15. Webcasts from these events will be available for 30 days on Angion’s website.

Angion Biomedica Corp (NASDAQ:ANGN) announced the first patient has been enrolled in the Phase 2 trial of ANG-3070, an oral tyrosine kinase receptor inhibitor aimed at treating primary proteinuric kidney diseases, such as focal segmental glomerulosclerosis and immunoglobulin A nephropathy. The trial includes 100 patients and will focus on the safety and efficacy of different dosages over 12 weeks. Angion ended 2021 with approximately $88.8 million in cash, expected to fund operations well into 2023. The company plans to file for a global Phase 2 trial for idiopathic pulmonary fibrosis by the end of 2022.

Angion Biomedica Corp. (NASDAQ: ANGN) and Vifor Pharma announced results from the Phase-II GUARD trial of ANG-3777, aimed at preventing acute kidney injury (AKI) during cardiac surgery. The trial did not achieve its primary endpoint of reduced serum creatinine levels compared to placebo (8.4% vs. 7.3%, p=0.77). However, a secondary endpoint, MAKE90, suggested potential benefits with fewer AKI events in the ANG-3777 group (14.7% vs. 21.5%, p=0.155). The overall safety profile was consistent with prior studies. Further data analysis is ongoing to determine next steps for ANG-3777.

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma announced results from the Phase 2 GUARD trial of ANG-3777, aimed at preventing acute kidney injury during cardiac surgery. The primary endpoint was not met, with ANG-3777 showing no significant difference in serum creatinine increase compared to placebo (8.4% vs. 7.3%, p=0.77). However, a secondary endpoint indicated potential benefits, with fewer patients in the treatment group experiencing a MAKE90 event (14.7% vs. 21.5%, p=0.155). The trial's safety profile was consistent with previous studies. Further analysis of the data is ongoing.

Angion Biomedica Corp (NASDAQ:ANGN) reported its financial results for the quarter ending September 30, 2021, with a net loss of $15.7 million, or $0.53 per diluted share. Although research and development expenses rose to $13.3 million due to clinical activities, the company ended the quarter with $102.7 million in cash. Angion aims to commence patient enrollment in its Phase 2 trial for ANG-3070 before year-end and is set to release Phase 2 data for ANG-3777 in Q4 2021. However, data from a recent Phase 3 trial of ANG-3777 showed no statistical significance on primary endpoints.

Angion Biomedica Corp (NASDAQ:ANGN) showcased four posters at the American Society of Nephrology’s Kidney Week 2021, highlighting promising preclinical data for its investigational candidate ANG-3070 in fibrotic kidney diseases. Key aspects included the Phase 2 trial design addressing primary proteinuric kidney diseases, with expectations to enroll the first patient by year-end 2021. Preclinical results demonstrated ANG-3070’s potential to reduce proteinuria and renal damage, emphasizing its therapeutic promise in addressing significant unmet needs in renal dysfunction.

Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 3:20 PM Eastern Time. The event will be led by Stifel Managing Director Annabel Samimy. A webcast will be available on Angion's investor relations page and archived for 30 days. Angion focuses on developing treatments for acute organ injuries and fibrotic diseases, with ongoing trials for its lead candidates, ANG-3777 for acute kidney injury and ANG-3070 for fibrotic disease.

Angion Biomedica Corp. (NASDAQ: ANGN) announced disappointing results from its phase-III trial of ANG-3777 for kidney transplant patients at risk for delayed graft function (DGF). The trial did not show a statistically significant difference in estimated Glomerular Filtration Rate (eGFR) compared to placebo at 12 months (53.3 vs. 50.4 mL/min/1.73m², p=0.33). Although there were minor indications of biological activity, the data did not support an indication in DGF. Further data analysis is ongoing to determine next steps.

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma announced that the Phase 3 trial for ANG-3777 did not show a statistically significant improvement in eGFR after 12 months among deceased donor kidney transplant patients at risk for delayed graft function. The results indicated 53.3 mL/min/1.73m² for ANG-3777 versus 50.4 mL/min/1.73m² for placebo (p=0.33). Although there were slight signals of activity, the findings suggest insufficient evidence to support an indication for ANG-3777 in this population. Angion expects to report cash equivalents of approximately $100 million in November 2021.